Sinomab Bioscience
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech developing novel monoclonal antibody therapies for immunology and oncology.
ImmunologyOncology
Technology Platform
Proprietary antibody discovery and engineering platform for developing humanized and fully human monoclonal antibodies.
Opportunities
Potential to address large autoimmune and oncology markets with novel biologic mechanisms.
Risk Factors
High clinical development risk and intense competition in the antibody space.
Competitive Landscape
Operates in the highly competitive global antibody therapeutics market, facing pressure from both large pharma and numerous agile biotechs.